NCT04910178View on ClinicalTrials.gov

Follow-up of NAFLD Patients With MRI-PDFF

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 1, 2021

Study Completion Date

December 30, 2021

Conditions
Diabetes Type 2NAFLD
Interventions
DRUG

Empagliflozin 25 MG

tablets to be taken orally once a day

DRUG

Ursodeoxycholic acid

tablets to be taken orally twice a day

DRUG

Pentoxifylline 400 MG

tablets to be taken orally twice a day

OTHER

placebo

just starch tablets without any active agents

Trial Locations (1)

61118

Minya University Hospital, Minya

All Listed Sponsors
lead

Asmaa Abdelfattah Elsayed

OTHER

NCT04910178 - Follow-up of NAFLD Patients With MRI-PDFF | Biotech Hunter | Biotech Hunter